MedTrace Logo

The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy

NCT04438603 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2020-08-28

No results posted yet for this study

Summary

This prospective study aims to investigate the role of IR-Seq in the diagnosis and disease monitoring in patients with IgA nephropathy.

Conditions

Interventions

DRUG

Intervention for incipient patients at low risk of disease progression

Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg

DRUG

Intervention for patients at high risk of disease progression

BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy: 1. If GFR\>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks. 2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks.

Sponsors & Collaborators

  • RenJi Hospital

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Shanghai University of Traditional Chinese Medicine

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-03-31
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04438603 on ClinicalTrials.gov